MCIA
TEVA icon

Mountain Capital Investment Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Mountain Capital Investment Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-120
Closed -$2K – 379
2017
Q3 		$2K Sell
120
-107
-47% -$2.41K ﹤0.01% 442
2017
Q2 		$8K Buy
+227
New +$7.03K 0.01% 328

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Mountain Capital Investment Advisors's TEVA Position: Q4 2017 in Review

Mountain Capital Investment Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 120 shares — an estimated $2K sold.

Mountain Capital Investment Advisors first reported a position in TEVA in Q2 2017 and held it in 2 quarters. The position peaked at $8K in Q2 2017. 508 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Mountain Capital Investment Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Mountain Capital Investment Advisors sold 120 Teva Pharmaceuticals shares in Q4 2017, an estimated $2K.
  • Mountain Capital Investment Advisors first reported a position in Teva Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Mountain Capital Investment Advisors's Teva Pharmaceuticals position peaked at $8K in Q2 2017.
  • 508 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Mountain Capital Investment Advisors's 13F filing for Q4 2017, filed 9 Feb 2018.